Results 91 to 100 of about 107,749 (252)

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis

Life
Abrocitinib, an oral small-molecule Janus Kinase 1 (JAK1) inhibitor, is primarily approved for treating moderate-to-severe atopic dermatitis (AD) in adults and adolescents aged 12 and older. This review examines the emerging off-label uses of Abrocitinib.
George G. Mitroi, George F. Mitroi, Oana Maria Ică, Florin Anghelina, Mircea Sorin Ciolofan, Mihaela Roxana Mitroi   +5 more
doaj   +1 more source

DENDRITIC CELL DIFFERENTIATION BLOCKED BY PRIMARY EFFUSION LYMPHOMA-RELEASED FACTORS IS PARTIALLY RESTORED BY INHIBITION OF P38 MAPK [PDF]

, 2010
To better understand the molecular mechanisms underlying the dendritic cell (DC) defects in cancer, we analyzed which signaling pathway is implicated in the abnormal monocyte differentiation into DC determined by the presence of Primary effusion lymphoma
CIRONE, Mara, DI RENZO, Livia Maria, FAGGIONI, Alberto, FRATI, Luigi, G. Borgia, G. Lucania, TRIVEDI, PANKAJ   +6 more
core   +2 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells

Tumor Biology, 2017
In this study, the combined effect of doxorubicin with cucurbitacin B on survival of anaplastic thyroid carcinoma cells was evaluated. For experiments, 8505C and CAL62 human anaplastic thyroid carcinoma cells were used.
Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee   +6 more
doaj   +1 more source

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Clinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa, Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Davide G. Ribaldone, Antonio Ferronato, Greta Lorenzon, Davide Checchin, Francesca Lambroglia, Francesco Ferrara, Carla Felice, Giovanni Cataletti, Giorgia Bodini, Andrea Pasta, Giovanni Aragona, Patrizia Perazzo, Federica Gaiani, Stefano Kayali, Fabio Cortellini, Francesco Costa, Lorenzo Bertani, Antonella Scarcelli, Mariaelena Serio, Emanuele Bendia, Laura Bolognini, Daniele Balducci, Claudia Quatraccioni, Francesco Martini, Michele Montori, Simona Piergallini, Francesca Maria Onidi, Paolo Usai Satta, Giorgia Orrù, Raffaele Colucci, Francesco Bachetti, Gabrio Bassotti, Elisabetta Antonelli, Costantino Zampaletta, Giulia Rocco, Carlotta Sacchi, Franco Scaldaferri, Daniele Napolitano, Roberto Faggiani, Michela Di Fonzo, Rita Monterubbianesi, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Roberta Pica, Maddalena Zippi, Andrea Cocco, Claudio Cassieri, Roberto Lorenzetti, Gian Marco Giorgetti, Valeria Clemente, Patrizio Scarozza, Girolamo Bevevino, Giulia Zerboni, Federico Iacopini, Giacomo Forti, Laurino Grossi, Serafina Fiorella, Giovanni Lombardi, Marta Patturelli, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Pietro Capone, Guido Daniele Villani, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Giuseppe Pranzo, Paolo Tonti, Viviana Neve, Libera Fanigliulo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Manuela Marzo, Ileana Luppino, Francesco Luzza, Rocco Spagnuolo, Stefano Rodinò, Ladislava Sebkova, Antonio De Medici, Domenico Catarella, Dario D’Agostino, Elisabetta Di Bartolo   +100 more
wiley   +1 more source

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Journal of Experimental Pharmacology, 2016
Jack W Singer,1 Suliman Al-Fayoumi,1 Haiching Ma,2 Rami S Komrokji,3 Ruben Mesa,4 Srdan Verstovsek5 1Translational Medicine, CTI BioPharma Corp., Seattle, WA, 2Department of Research and Development, Reaction Biology, Malvern, PA, 3Department of ...
Singer J, Al-Fayoumi S, Ma H, Komrokji R, Mesa R, Verstovsek S   +5 more
doaj  

The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review

Dermatology and Therapy
Alopecia areata is an inflammatory autoimmune disease that presents as non-scarring hair loss in adults and children and causes substantial psychological distress, economic burden, and reduced quality of life for those affected.
Hussein Abdel Dayem, Anwar Al Hammadi, Ashraf Reda, Fatima Albreiki, Ayman Al Naeem, Ahmed Ameen, Mohamed Ahmed, Huda Rajab Ali, Mohamed Elrayes, Gozde Senay, Muna Al Murrawi   +10 more
doaj   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

On the Mechanism of Action of Anti-Inflammatory Activity of Hypericin: An In Silico Study Pointing to the Relevance of Janus Kinases Inhibition

Molecules, 2018
St. John’s Wort (Hypericum perforatum L.) flowers are commonly used in ethnomedical preparations with promising outcomes to treat inflammation both per os and by topical application. However, the underlying molecular mechanisms need to be described
Luca Dellafiora, Gianni Galaverna, Gabriele Cruciani, Chiara Dall’Asta, Renato Bruni   +4 more
doaj   +1 more source